Header Logo

Connection

Leslie Shaw to Alzheimer Disease

Back to Details
This is a "connection" page, showing publications Leslie Shaw has written about Alzheimer Disease.
Leslie Shaw
Connection Strength
15.858
Alzheimer Disease
  1. Shaw LM, Korecka M, Lee EB, Cousins KAQ, Vanderstichele H, Schindler SE, Tosun D, DeMarco ML, Brylska M, Wan Y, Burnham S, Sciulli A, Vulaj A, Tropea TF, Chen-Plotkin A, Wolk DA. ADNI Biomarker Core: A review of progress since 2004 and future challenges. Alzheimers Dement. 2025 Jan; 21(1):e14264.
    View in: PubMed
    Score: 0.581
  2. Kang JH, Korecka M, Lee EB, Cousins KAQ, Tropea TF, Chen-Plotkin AA, Irwin DJ, Wolk D, Brylska M, Wan Y, Shaw LM. Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology. Clin Chem. 2023 11 02; 69(11):1247-1259.
    View in: PubMed
    Score: 0.539
  3. Shaw LM, Galasko D. Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD. Ann Neurol. 2023 10; 94(4):618-619.
    View in: PubMed
    Score: 0.536
  4. Shaw LM, Vanderstichele H, Knapik-Czajka M, Blennow K, Trojanowski JQ. Establishing an Autopsy-Based Cerebrospinal Fluid Biomarker Signature in Alzheimer Disease Patients. Clin Chem. 2022 10 06; 68(10):1336-1337.
    View in: PubMed
    Score: 0.500
  5. Hajjar I, Yang Z, Okafor M, Liu C, Waligorska T, Goldstein FC, Shaw LM. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors. JAMA Netw Open. 2022 10 03; 5(10):e2235068.
    View in: PubMed
    Score: 0.500
  6. Korecka M, Shaw LM. Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. J Neurochem. 2021 10; 159(2):211-233.
    View in: PubMed
    Score: 0.463
  7. Shaw LM, Korecka M, Figurski M, Toledo J, Irwin D, Hee Kang J, Trojanowski JQ. Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. J Appl Lab Med. 2020 01 01; 5(1):183-193.
    View in: PubMed
    Score: 0.413
  8. Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, Kim EJ, Wolk DA, Bennett DA, Chen-Plotkin A, Grossman M, Hu W, Lee VM, Mackin RS, Trojanowski JQ, Wilson RS, Shaw LM. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry. 2012 Jan 03; 2:e65.
    View in: PubMed
    Score: 0.237
  9. Dean RA, Shaw LM. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. Clin Chem. 2010 Jan; 56(1):7-9.
    View in: PubMed
    Score: 0.205
  10. Duong MT, Das SR, Khandelwal P, Lyu X, Xie L, McGrew E, Dehghani N, McMillan CT, Lee EB, Shaw LM, Yushkevich PA, Wolk DA, Nasrallah IM. Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer's and Lewy body disease. Brain. 2025 May 13; 148(5):1577-1587.
    View in: PubMed
    Score: 0.150
  11. Wang G, Li Y, Xiong C, Cao Y, Schindler SE, McDade E, Blennow K, Hansson O, Dage JL, Jack CR, Teunissen CE, Shaw LM, Zetterberg H, Ibanez L, Timsina J, Carlos C, Bateman RJ. The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation. Alzheimers Dement. 2025 Apr; 21(4):e14587.
    View in: PubMed
    Score: 0.149
  12. Leuzy A, Bollack A, Pellegrino D, Teunissen CE, La Joie R, Rabinovici GD, Franzmeier N, Johnson K, Barkhof F, Shaw LM, Arkhipenko A, Schindler SE, Honig LS, Moscoso Rial A, Sch?ll M, Zetterberg H, Blennow K, Hansson O, Farrar G. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. Alzheimers Dement. 2025 Mar; 21(3):e14528.
    View in: PubMed
    Score: 0.148
  13. Ashton NJ, Keshavan A, Brum WS, Andreasson U, Arslan B, Droescher M, Barghorn S, Vanbrabant J, Lambrechts C, Van Loo M, Stoops E, Iyengar S, Ji H, Xu X, Forrest-Hay A, Zhang B, Luo Y, Jeromin A, Vandijck M, Bastard NL, Kolb H, Triana-Baltzer G, Bali D, Janelidze S, Yang SY, Demos C, Romero D, Sigal G, Wohlstadter J, Malyavantham K, Khare M, Jethwa A, Stoeckl L, Gobom J, Kac PR, Gonzalez-Ortiz F, Montoliu-Gaya L, Hansson O, Rissman RA, Carrillo MC, Shaw LM, Blennow K, Schott JM, Zetterberg H. The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study. Alzheimers Dement. 2025 Feb; 21(2):e14508.
    View in: PubMed
    Score: 0.147
  14. Weiner MW, Kanoria S, Miller MJ, Aisen PS, Beckett LA, Conti C, Diaz A, Flenniken D, Green RC, Harvey DJ, Jack CR, Jagust W, Lee EB, Morris JC, Nho K, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Veitch DP. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimers Dement. 2025 Jan; 21(1):e14321.
    View in: PubMed
    Score: 0.146
  15. Tosun D, Hausle Z, Thropp P, Concha-Marambio L, Lamoureux J, Lebovitz R, Shaw LM, Singleton AB, Weiner MW, Blauwendraat C. Association of CSF a-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study. Alzheimers Dement. 2024 Dec; 20(12):8444-8460.
    View in: PubMed
    Score: 0.144
  16. Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, Li Y, Coomaraswamy J, Baratta M, Mordashova Y, Saad ZS, Raunig DL, Ashton NJ, Meyers EA, Rubel CE, Rosenbaugh EG, Bannon AW, Potter WZ. Head-to-head comparison of leading blood tests for Alzheimer's disease pathology. Alzheimers Dement. 2024 Nov; 20(11):8074-8096.
    View in: PubMed
    Score: 0.144
  17. Liu S, Park T, Kr?ger DM, Pena-Centeno T, Burkhardt S, Schutz AL, Huang YN, Rosewood T, Chaudhuri S, Cho M, Risacher SL, Wan Y, Shaw LM, Sananbenesi F, Brodsky AS, Lin H, Krunic A, Blusztajn JK, Saykin AJ, Delalle I, Fischer A, Nho K. Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers. Alzheimers Dement. 2024 Nov; 20(11):7698-7714.
    View in: PubMed
    Score: 0.143
  18. Kr?ger DM, Pena-Centeno T, Liu S, Park T, Kaurani L, Pradhan R, Huang YN, Risacher SL, Burkhardt S, Sch?tz AL, Wan Y, Shaw LM, Brodsky AS, DeStefano AL, Lin H, Schroeder R, Krunic A, Hempel N, Sananbenesi F, Blusztajn JK, Saykin AJ, Delalle I, Nho K, Fischer A. The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals. Alzheimers Dement. 2024 Nov; 20(11):7479-7494.
    View in: PubMed
    Score: 0.143
  19. Miller MJ, Diaz A, Conti C, Albala B, Flenniken D, Fockler J, Kwang W, Sacrey DT, Ashford MT, Skirrow C, Weston J, Fristed E, Farias ST, Korecka M, Wan Y, Aisen PS, Beckett L, Harvey D, Lee EB, Petersen RC, Shaw LM, Okonkwo OC, Mindt MR, Weiner MW, Nosheny RL. The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research. Alzheimers Dement. 2024 Oct; 20(10):7232-7247.
    View in: PubMed
    Score: 0.143
  20. Xiong C, Luo J, Wolk DA, Shaw LM, Roberson ED, Murchison CF, Henson RL, Benzinger TLS, Bui Q, Agboola F, Grant E, Gremminger EN, Moulder KL, Geldmacher DS, Clay OJ, Babulal G, Cruchaga C, Holtzman DM, Bateman RJ, Morris JC, Schindler SE. Baseline levels and longitudinal changes in plasma A?42/40 among Black and white individuals. Nat Commun. 2024 Jul 02; 15(1):5539.
    View in: PubMed
    Score: 0.141
  21. Tosun D, Hausle Z, Iwaki H, Thropp P, Lamoureux J, Lee EB, MacLeod K, McEvoy S, Nalls M, Perrin RJ, Saykin AJ, Shaw LM, Singleton AB, Lebovitz R, Weiner MW, Blauwendraat C. A cross-sectional study of a-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function. Alzheimers Dement. 2024 08; 20(8):5114-5131.
    View in: PubMed
    Score: 0.140
  22. Brown C, Das S, Xie L, Nasrallah I, Detre J, Chen-Plotkin A, Shaw L, McMillan C, Yushkevich P, Wolk D. Medial temporal lobe gray matter microstructure in preclinical Alzheimer's disease. Alzheimers Dement. 2024 06; 20(6):4147-4158.
    View in: PubMed
    Score: 0.140
  23. Reese M, Wong MK, Cheong V, Ha CI, Cooter Wright M, Browndyke J, Moretti E, Devinney MJ, Habib AS, Moul JW, Shaw LM, Waligorska T, Whitson HE, Cohen HJ, Welsh-Bohmer KA, Plassman BL, Mathew JP, Berger M. Cognitive and Cerebrospinal Fluid Alzheimer's Disease-related Biomarker Trajectories in Older Surgical Patients and Matched Nonsurgical Controls. Anesthesiology. 2024 May 01; 140(5):963-978.
    View in: PubMed
    Score: 0.139
  24. Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud TM, Toga AW, Tanner CM, Kieburtz KD, Mollenhauer B, Galasko D, Hutten S, Weintraub D, Siderowf AD, Marek K, Poston KL, Shaw LM. Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease. Neurology. 2024 Feb; 102(4):e208033.
    View in: PubMed
    Score: 0.137
  25. Bonomi S, Lu R, Schindler SE, Bui Q, Lah JJ, Wolk D, Gleason CE, Sperling R, Roberson ED, Levey AI, Shaw L, Van Hulle C, Benzinger T, Adams M, Manzanares C, Qiu D, Hassenstab J, Moulder KL, Balls-Berry JE, Johnson K, Johnson SC, Murchison CF, Luo J, Gremminger E, Agboola F, Grant EA, Hornbeck R, Massoumzadeh P, Keefe S, Dierker D, Gray J, Henson RL, Streitz M, Mechanic-Hamilton D, Morris JC, Xiong C. Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals. Ann Neurol. 2024 Mar; 95(3):495-506.
    View in: PubMed
    Score: 0.136
  26. Xiong C, Schindler SE, Henson RL, Wolk DA, Shaw LM, Agboola F, Morris JC, Lu R, Luo J. Correlational analyses of biomarkers that are harmonized through a bridging study due to measurement errors. Stat Methods Med Res. 2024 Feb; 33(2):185-202.
    View in: PubMed
    Score: 0.135
  27. Veitch DP, Weiner MW, Miller M, Aisen PS, Ashford MA, Beckett LA, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Nho KT, Nosheny R, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin A, Shaw LM, Toga AW, Tosun D. The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022. Alzheimers Dement. 2024 01; 20(1):652-694.
    View in: PubMed
    Score: 0.133
  28. Haque R, Watson CM, Liu J, Carter EK, Duong DM, Lah JJ, Wingo AP, Roberts BR, Johnson ECB, Saykin AJ, Shaw LM, Seyfried NT, Wingo TS, Levey AI. A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease. Sci Transl Med. 2023 09 06; 15(712):eadg4122.
    View in: PubMed
    Score: 0.133
  29. Groechel RC, Tripodis Y, Alosco ML, Mez J, Qiao Qiu W, Goldstein L, Budson AE, Kowall NW, Shaw LM, Weiner M, Jack CR, Killiany RJ. Biomarkers of Alzheimer's disease in Black and/or African American Alzheimer's Disease Neuroimaging Initiative (ADNI)?participants. Neurobiol Aging. 2023 11; 131:144-152.
    View in: PubMed
    Score: 0.132
  30. Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O'Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Schindler SE. Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape. Neuron. 2023 09 20; 111(18):2781-2799.
    View in: PubMed
    Score: 0.131
  31. Villalobos D, Reese M, Wright MC, Wong M, Syed A, Park J, Hall A, Browndyke JN, Martucci KT, Devinney MJ, Acker L, Moretti EW, Talbot L, Colin B, Ohlendorf B, Waligorska T, Shaw LM, Whitson HE, Cohen HJ, Mathew JP, Berger M. Perioperative changes in neurocognitive and Alzheimer's disease-related cerebrospinal fluid biomarkers in older patients randomised to isoflurane or propofol for anaesthetic maintenance. Br J Anaesth. 2023 08; 131(2):328-337.
    View in: PubMed
    Score: 0.131
  32. Xie L, Das SR, Wisse LEM, Ittyerah R, de Flores R, Shaw LM, Yushkevich PA, Wolk DA. Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer's disease. Alzheimers Res Ther. 2023 04 11; 15(1):79.
    View in: PubMed
    Score: 0.130
  33. Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, Wolk DA, Weintraub D, Spindler M, Deik A, Grossman M, Tropea TF. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. Ann Clin Transl Neurol. 2023 05; 10(5):802-813.
    View in: PubMed
    Score: 0.129
  34. Deming Y, Vasiljevic E, Morrow A, Miao J, Van Hulle C, Jonaitis E, Ma Y, Whitenack V, Kollmorgen G, Wild N, Suridjan I, Shaw LM, Asthana S, Carlsson CM, Johnson SC, Zetterberg H, Blennow K, Bendlin BB, Lu Q, Engelman CD. Neuropathology-based APOE genetic risk score better quantifies Alzheimer's risk. Alzheimers Dement. 2023 08; 19(8):3406-3416.
    View in: PubMed
    Score: 0.128
  35. Kim BJ, Grossman M, Aleman TS, Song D, Cousins KAQ, McMillan CT, Saludades A, Yu Y, Lee EB, Wolk D, Van Deerlin VM, Shaw LM, Ying GS, Irwin DJ. Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's disease. Neurobiol Aging. 2023 05; 125:74-82.
    View in: PubMed
    Score: 0.128
  36. Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, Lopez S, Ovod V, Nakamura A, Shaw LM, Zetterberg H, Hansson O, Bateman RJ. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther. 2022 12 27; 14(1):195.
    View in: PubMed
    Score: 0.127
  37. Ko YA, Billheimer JT, Lyssenko NN, Kueider-Paisley A, Wolk DA, Arnold SE, Leung YY, Shaw LM, Trojanowski JQ, Kaddurah-Daouk RF, Kling MA, Rader DJ. ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer's disease. Alzheimers Res Ther. 2022 12 26; 14(1):194.
    View in: PubMed
    Score: 0.127
  38. Tropea TF, Waligorska T, Xie SX, Nasrallah IM, Cousins KAQ, Trojanowski JQ, Grossman M, Irwin DJ, Weintraub D, Lee EB, Wolk DA, Chen-Plotkin AS, Shaw LM. Plasma phosphorylated tau181 predicts cognitive and functional decline. Ann Clin Transl Neurol. 2023 01; 10(1):18-31.
    View in: PubMed
    Score: 0.127
  39. Cousins KAQ, Arezoumandan S, Shellikeri S, Ohm D, Shaw LM, Grossman M, Wolk D, McMillan CT, Chen-Plotkin A, Lee E, Trojanowski JQ, Zetterberg H, Blennow K, Irwin DJ. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant a-Synuclein Pathology. Neurology. 2022 Nov 14; 99(20):e2303-e2312.
    View in: PubMed
    Score: 0.126
  40. Toledo JB, Rashid T, Liu H, Launer L, Shaw LM, Heckbert SR, Weiner M, Seshadri S, Habes M. SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline. PLoS One. 2022; 17(11):e0276392.
    View in: PubMed
    Score: 0.126
  41. Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS, Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, Fagan AM, Farlow M, Fox NC, Ghetti B, Goate AM, Gordon BA, Graff-Radford N, Day GS, Hassenstab J, Ikeuchi T, Jack CR, Jagust WJ, Jucker M, Levin J, Massoumzadeh P, Masters CL, Martins R, McDade E, Mori H, Noble JM, Petersen RC, Ringman JM, Salloway S, Saykin AJ, Schofield PR, Shaw LM, Toga AW, Trojanowski JQ, V?glein J, Weninger S, Bateman RJ, Buckles VD. Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. Brain. 2022 10 21; 145(10):3594-3607.
    View in: PubMed
    Score: 0.125
  42. Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, Grossman M, Irwin DJ, Trojanowski JQ, Zetterberg H, Blennow K, Brinkmalm A. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. Alzheimers Dement. 2023 05; 19(5):1775-1784.
    View in: PubMed
    Score: 0.125
  43. Weiner MW, Veitch DP, Miller MJ, Aisen PS, Albala B, Beckett LA, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Trojanowski JQ. Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Alzheimers Dement. 2023 01; 19(1):307-317.
    View in: PubMed
    Score: 0.125
  44. ?hrfelt A, Benedet AL, Ashton NJ, Kvartsberg H, Vandijck M, Weiner MW, Trojanowski JQ, Shaw LM, Zetterberg H, Blennow K. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals. Neurology. 2023 01 17; 100(3):e275-e285.
    View in: PubMed
    Score: 0.125
  45. Cousins KAQ, Shaw LM, Shellikeri S, Dratch L, Rosario L, Elman LB, Quinn C, Amado DA, Wolk DA, Tropea TF, Chen-Plotkin A, Irwin DJ, Grossman M, Lee EB, Trojanowski JQ, McMillan CT. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis. Ann Neurol. 2022 11; 92(5):807-818.
    View in: PubMed
    Score: 0.124
  46. Hampel H, Elhage A, Shaw LM, Aisen P, Chen C, Lle? A, Iwatsubo T, Iwata A, Yamada M, Ikeuchi T, Jia J, Wang H, Teunissen CE, Peskind E, Blennow K, Cummings J, Vergallo A. The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary. Neurodegener Dis Manag. 2022 10; 12(5):221-229.
    View in: PubMed
    Score: 0.123
  47. Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, Baratta M, Kolb HC, Dobler I, Mordashova Y, Saad ZS, Raunig DL, Spanakis EM, Li Y, Schindler SE, Ferber K, Rubel CE, Martone RL, Weber CJ, Edelmayer RM, Meyers EA, Bollinger JG, Rosenbaugh EG, Potter WZ. Comparative analytical performance of multiple plasma A?42 and A?40 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimers Dement. 2023 03; 19(3):956-966.
    View in: PubMed
    Score: 0.123
  48. Tian C, Stewart T, Hong Z, Guo Z, Aro P, Soltys D, Pan C, Peskind ER, Zabetian CP, Shaw LM, Galasko D, Quinn JF, Shi M, Zhang J. Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's disease. Alzheimers Dement. 2023 03; 19(3):909-923.
    View in: PubMed
    Score: 0.123
  49. Weiner MW, Harvey D, Landau SM, Veitch DP, Neylan TC, Grafman JH, Aisen PS, Petersen RC, Jack CR, Tosun D, Shaw LM, Trojanowski JQ, Saykin AJ, Hayes J, De Carli C. Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. Alzheimers Dement. 2023 03; 19(3):884-895.
    View in: PubMed
    Score: 0.123
  50. Walker IM, Cousins KA, Siderowf A, Duda JE, Morley JF, Dahodwala N, Tropea T, Vaishnavi S, Wolk DA, Chen-Plotkin AS, Shaw LM, Lee EB, Trojanowski JQ, Grossman M, Weintraub D, Irwin DJ. Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. Parkinsonism Relat Disord. 2022 07; 100:33-36.
    View in: PubMed
    Score: 0.122
  51. Weinshel S, Irwin DJ, Zhang P, Weintraub D, Shaw LM, Siderowf A, Xie SX. Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease. J Parkinsons Dis. 2022; 12(4):1155-1167.
    View in: PubMed
    Score: 0.119
  52. Delaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, Beaume A, Bedel A, Bellomo G, Bigot-Corbel E, Bjerke M, Blanc-Quintin MC, Boada M, Bousiges O, Chapman MD, DeMarco ML, D'Onofrio M, Dumurgier J, Dufour-Rainfray D, Engelborghs S, Esselmann H, Fogli A, Gabelle A, Galloni E, Gondolf C, Grandhomme F, Grau-Rivera O, Hart M, Ikeuchi T, Jeromin A, Kasuga K, Keshavan A, Khalil M, K?rtvelyessy P, Kulczynska-Przybik A, Laplanche JL, Lewczuk P, Li QX, Lle? A, Malaplate C, Marqui? M, Masters CL, Mroczko B, Nogueira L, Orellana A, Otto M, Oudart JB, Paquet C, Paoletti FP, Parnetti L, Perret-Liaudet A, Peoc'h K, Poesen K, Puig-Pijoan A, Quadrio I, Quillard-Muraine M, Rucheton B, Schraen S, Schott JM, Shaw LM, Su?rez-Calvet M, Tsolaki M, Tumani H, Udeh-Momoh CT, Vaudran L, Verbeek MM, Verde F, Vermunt L, Vogelgsang J, Wiltfang J, Zetterberg H, Lehmann S. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimers Dement. 2022 10; 18(10):1868-1879.
    View in: PubMed
    Score: 0.118
  53. Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. Validation of Plasma Amyloid-? 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology. 2022 02 15; 98(7):e688-e699.
    View in: PubMed
    Score: 0.118
  54. Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, Fandos N, Hansson O, Hirtz C, Janelidze S, Kang S, Kirmess K, Kindermans J, Lee R, Meyer MR, Shan D, Shaw LM, Waligorska T, West T, Zetterberg H, Edelmayer RM, Teunissen CE. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022 08; 18(8):1484-1497.
    View in: PubMed
    Score: 0.118
  55. Tosun D, Demir Z, Veitch DP, Weintraub D, Aisen P, Jack CR, Jagust WJ, Petersen RC, Saykin AJ, Shaw LM, Trojanowski JQ, Weiner MW. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimers Dement. 2022 07; 18(7):1370-1382.
    View in: PubMed
    Score: 0.117
  56. Veitch DP, Weiner MW, Aisen PS, Beckett LA, DeCarli C, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Trojanowski JQ. Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimers Dement. 2022 04; 18(4):824-857.
    View in: PubMed
    Score: 0.117
  57. Hampel H, Shaw LM, Aisen P, Chen C, Lle? A, Iwatsubo T, Iwata A, Yamada M, Ikeuchi T, Jia J, Wang H, Teunissen CE, Peskind E, Blennow K, Cummings J, Vergallo A. State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimers Dement. 2022 01; 18(1):159-177.
    View in: PubMed
    Score: 0.114
  58. Libiger O, Shaw LM, Watson MH, Nairn AC, Uma?a KL, Biarnes MC, Canet-Avil?s RM, Jack CR, Breton YA, Cortes L, Chelsky D, Spellman DS, Baker SA, Raghavan N, Potter WZ. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimers Dement. 2021 12; 17(12):1976-1987.
    View in: PubMed
    Score: 0.113
  59. Moon S, Kim S, Mankhong S, Choi SH, Vandijck M, Kostanjevecki V, Jeong JH, Yoon SJ, Park KW, Kim EJ, Yoon B, Kim HJ, Jang JW, Hong JY, Park DH, Shaw LM, Kang JH. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Alzheimers Res Ther. 2021 01 12; 13(1):22.
    View in: PubMed
    Score: 0.111
  60. Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust W, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. Editorial: How Will Aducanumab Approval Impact AD Research? J Prev Alzheimers Dis. 2021; 8(4):391-392.
    View in: PubMed
    Score: 0.111
  61. Cousins KAQ, Phillips JS, Irwin DJ, Lee EB, Wolk DA, Shaw LM, Zetterberg H, Blennow K, Burke SE, Kinney NG, Gibbons GS, McMillan CT, Trojanowski JQ, Grossman M. ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimers Dement. 2021 05; 17(5):822-830.
    View in: PubMed
    Score: 0.110
  62. Spotorno N, Coughlin DG, Olm CA, Wolk D, Vaishnavi SN, Shaw LM, Dahodwala N, Morley JF, Duda JE, Deik AF, Spindler MA, Chen-Plotkin A, Lee EB, Trojanowski JQ, McMillan CT, Weintraub D, Grossman M, Irwin DJ. Tau pathology associates with in vivo cortical thinning in Lewy body disorders. Ann Clin Transl Neurol. 2020 12; 7(12):2342-2355.
    View in: PubMed
    Score: 0.109
  63. Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Su?rez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Sch?ll M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K, Zetterberg H. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol Psychiatry. 2021 02; 26(2):429-442.
    View in: PubMed
    Score: 0.109
  64. Franzmeier N, Su?rez-Calvet M, Frontzkowski L, Moore A, Hohman TJ, Morenas-Rodriguez E, Nuscher B, Shaw L, Trojanowski JQ, Dichgans M, Kleinberger G, Haass C, Ewers M. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Mol Neurodegener. 2020 10 08; 15(1):57.
    View in: PubMed
    Score: 0.109
  65. Guo T, Korman D, La Joie R, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM. Normalization of CSF pTau measurement by A?40 improves its performance as a biomarker of Alzheimer's disease. Alzheimers Res Ther. 2020 08 15; 12(1):97.
    View in: PubMed
    Score: 0.108
  66. Ewers M, Biechele G, Su?rez-Calvet M, Sacher C, Blume T, Morenas-Rodriguez E, Deming Y, Piccio L, Cruchaga C, Kleinberger G, Shaw L, Trojanowski JQ, Herms J, Dichgans M, Brendel M, Haass C, Franzmeier N. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med. 2020 09 07; 12(9):e12308.
    View in: PubMed
    Score: 0.108
  67. Kling MA, Goodenowe DB, Senanayake V, MahmoudianDehkordi S, Arnold M, Massaro TJ, Baillie R, Han X, Leung YY, Saykin AJ, Nho K, Kueider-Paisley A, Tenenbaum JD, Wang LS, Shaw LM, Trojanowski JQ, Kaddurah-Daouk RF. Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. Alzheimers Dement. 2020 09; 16(9):1234-1247.
    View in: PubMed
    Score: 0.107
  68. Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Weintraub D, Mollenhauer B, Galasko DR, Siderowf A, Marek K, Trojanowski JQ, Shaw LM. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Ann Neurol. 2020 09; 88(3):574-587.
    View in: PubMed
    Score: 0.107
  69. Cousins KAQ, Irwin DJ, Wolk DA, Lee EB, Shaw LMJ, Trojanowski JQ, Da Re F, Gibbons GS, Grossman M, Phillips JS. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. Brain. 2020 07 01; 143(7):2295-2311.
    View in: PubMed
    Score: 0.107
  70. Arnold M, Nho K, Kueider-Paisley A, Massaro T, Huynh K, Brauner B, MahmoudianDehkordi S, Louie G, Moseley MA, Thompson JW, John-Williams LS, Tenenbaum JD, Blach C, Chang R, Brinton RD, Baillie R, Han X, Trojanowski JQ, Shaw LM, Martins R, Weiner MW, Trushina E, Toledo JB, Meikle PJ, Bennett DA, Krumsiek J, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R, Kastenm?ller G. Sex and APOE e4 genotype modify the Alzheimer's disease serum metabolome. Nat Commun. 2020 03 02; 11(1):1148.
    View in: PubMed
    Score: 0.104
  71. Cipollari E, Szapary HJ, Picataggi A, Billheimer JT, Lyssenko CA, Ying GS, Shaw LM, Kling MA, Kaddurah-Daouk R, Rader DJ, Pratic? D, Lyssenko NN. Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease. J Alzheimers Dis. 2020; 74(2):563-578.
    View in: PubMed
    Score: 0.103
  72. Okafor M, Nye JA, Shokouhi M, Shaw LM, Goldstein F, Hajjar I. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease. J Alzheimers Dis. 2020; 74(2):589-601.
    View in: PubMed
    Score: 0.103
  73. Schindler SE, Jicha GA, Nelson PT, Keene CD, Blennow K, Molinuevo JL, Masters CL, Hansson O, Teunissen CE, Galasko D, Shaw LM, Levey AI, Silverberg N. Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. J Alzheimers Dis. 2020; 76(1):27-31.
    View in: PubMed
    Score: 0.103
  74. Trammell AR, McDaniel DJ, Obideen M, Okafor M, Thomas TL, Goldstein FC, Shaw LM, Hajjar IM. Perceived Stress is Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in African Americans with Mild Cognitive Impairment. J Alzheimers Dis. 2020; 77(2):843-853.
    View in: PubMed
    Score: 0.103
  75. Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, Wahl S, Eichenlaub U, Lifke V, Simon M, Trojanowski JQ, Hansson O. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys A?(1-42), pTau and tTau CSF immunoassays. Sci Rep. 2019 12 13; 9(1):19024.
    View in: PubMed
    Score: 0.103
  76. Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, Bush WS, Gifford KA, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Deming Y, Chao MJ, Huentelman M, Martin ER, Hamilton-Nelson K, Shaw LM, Trojanowski JQ, Peskind ER, Cruchaga C, Pericak-Vance MA, Goate AM, Cox NJ, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Bennett DA, Schneider JA, Jefferson AL, Hohman TJ. Sex differences in the genetic predictors of Alzheimer's pathology. Brain. 2019 09 01; 142(9):2581-2589.
    View in: PubMed
    Score: 0.101
  77. Ewers M, Franzmeier N, Su?rez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M, Trojanowski JQ, Shaw LM, Weiner MW, Haass C. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med. 2019 08 28; 11(507).
    View in: PubMed
    Score: 0.101
  78. Nho K, Kueider-Paisley A, Ahmad S, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenm?ller G, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn C, Saykin AJ, Kaddurah-Daouk R. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Netw Open. 2019 07 03; 2(7):e197978.
    View in: PubMed
    Score: 0.100
  79. Phillips JS, Da Re F, Irwin DJ, McMillan CT, Vaishnavi SN, Xie SX, Lee EB, Cook PA, Gee JC, Shaw LM, Trojanowski JQ, Wolk DA, Grossman M. Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease. Brain. 2019 06 01; 142(6):1701-1722.
    View in: PubMed
    Score: 0.099
  80. Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K. Method comparison study of the Elecsys? ?-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. Clin Biochem. 2019 Oct; 72:7-14.
    View in: PubMed
    Score: 0.099
  81. Gibbons GS, Kim SJ, Robinson JL, Changolkar L, Irwin DJ, Shaw LM, Lee VM, Trojanowski JQ. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). Acta Neuropathol Commun. 2019 03 04; 7(1):34.
    View in: PubMed
    Score: 0.097
  82. Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2019 05; 15(5):655-665.
    View in: PubMed
    Score: 0.097
  83. Olsson B, Portelius E, Cullen NC, Sandelius ?, Zetterberg H, Andreasson U, H?glund K, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk D, McCluskey L, Elman L, Shaw LM, Toledo JB, McBride J, Hernandez-Con P, Lee VM, Trojanowski JQ, Blennow K. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurol. 2019 03 01; 76(3):318-325.
    View in: PubMed
    Score: 0.097
  84. Stewart T, Shi M, Mehrotra A, Aro P, Soltys D, Kerr KF, Zabetian CP, Peskind ER, Taylor P, Shaw LM, Trojanowski JQ, Zhang J. Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. J Alzheimers Dis. 2019; 69(1):263-276.
    View in: PubMed
    Score: 0.096
  85. Toledo JB, Habes M, Sotiras A, Bjerke M, Fan Y, Weiner MW, Shaw LM, Davatzikos C, Trojanowski JQ. APOE Effect on Amyloid-? PET Spatial Distribution, Deposition Rate, and Cut-Points. J Alzheimers Dis. 2019; 69(3):783-793.
    View in: PubMed
    Score: 0.096
  86. MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, Louie G, Kueider-Paisley A, Moseley MA, Thompson JW, St John Williams L, Tenenbaum JD, Blach C, Baillie R, Han X, Bhattacharyya S, Toledo JB, Schafferer S, Klein S, Koal T, Risacher SL, Kling MA, Motsinger-Reif A, Rotroff DM, Jack J, Hankemeier T, Bennett DA, De Jager PL, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn CM, Saykin AJ, Kastenm?ller G, Kaddurah-Daouk R. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. Alzheimers Dement. 2019 01; 15(1):76-92.
    View in: PubMed
    Score: 0.095
  87. Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenm?ller G, Jia W, Xie G, Ahmad S, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimers Dement. 2019 02; 15(2):232-244.
    View in: PubMed
    Score: 0.095
  88. Gangishetti U, Christina Howell J, Perrin RJ, Louneva N, Watts KD, Kollhoff A, Grossman M, Wolk DA, Shaw LM, Morris JC, Trojanowski JQ, Fagan AM, Arnold SE, Hu WT. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther. 2018 09 25; 10(1):98.
    View in: PubMed
    Score: 0.095
  89. Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimers Dement. 2018 10; 14(10):1313-1333.
    View in: PubMed
    Score: 0.093
  90. Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM. CSF biomarkers of Alzheimer's disease concord with amyloid-? PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018 11; 14(11):1470-1481.
    View in: PubMed
    Score: 0.091
  91. Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Kim S, Saykin AJ, De Jager PL, Albert M, Moghekar A, O'Brien R, Riemenschneider M, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Schellenberg G, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Peskind ER, Li G, Di Narzo AF, Kauwe JS, Goate AM, Cruchaga C. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Acta Neuropathol. 2017 05; 133(5):839-856.
    View in: PubMed
    Score: 0.085
  92. Brown CA, Johnson NF, Anderson-Mooney AJ, Jicha GA, Shaw LM, Trojanowski JQ, Van Eldik LJ, Schmitt FA, Smith CD, Gold BT. Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. Neuroimage Clin. 2017; 13:106-115.
    View in: PubMed
    Score: 0.083
  93. Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O' Hara R, Ashford JW, Shaw LM. Active Cigarette Smoking in?Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers. J Alzheimers Dis. 2016 07 25; 54(1):99-107.
    View in: PubMed
    Score: 0.081
  94. Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, Bittner T, Korecka M, Jenkins RG, Vanderstichele H, Stoops E, Lewczuk P, Shaw LM, Zegers I, Schimmel H, Zetterberg H, Blennow K. CSF A?1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. Clin Chim Acta. 2017 Apr; 467:27-33.
    View in: PubMed
    Score: 0.080
  95. Berger M, Nadler JW, Friedman A, McDonagh DL, Bennett ER, Cooter M, Qi W, Laskowitz DT, Ponnusamy V, Newman MF, Shaw LM, Warner DS, Mathew JP, James ML. The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial. J Alzheimers Dis. 2016 04 15; 52(4):1299-310.
    View in: PubMed
    Score: 0.080
  96. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW. Independent information from cerebrospinal fluid amyloid-? and florbetapir imaging in Alzheimer's disease. Brain. 2015 Mar; 138(Pt 3):772-83.
    View in: PubMed
    Score: 0.073
  97. Siemers E, Dean RA, DeMattos RB, Hutton ML, Blennow K, Shaw LM, Holtzman DM. Anti-A? antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803-810 (2014). Acta Neuropathol. 2014 Oct; 128(4):609-10.
    View in: PubMed
    Score: 0.071
  98. Paterson RW, Bartlett JW, Blennow K, Fox NC, Shaw LM, Trojanowski JQ, Zetterberg H, Schott JM. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. 2014 Jul 29; 4:e419.
    View in: PubMed
    Score: 0.071
  99. Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, Jagust W, Jack C, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun. 2014 Mar 06; 2:26.
    View in: PubMed
    Score: 0.069
  100. Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, Montine TJ, Trojanowski JQ, Shaw LM, Ashford JW, Tezapsidis N. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res. 2014 Feb; 11(2):165-74.
    View in: PubMed
    Score: 0.069
  101. Hu WT, Shaw LM, Trojanowski JQ. Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on? Acta Neuropathol. 2013 Nov; 126(5):625-9.
    View in: PubMed
    Score: 0.067
  102. Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM, Tosun D, Weiner M. CSF protein biomarkers predicting longitudinal reduction of CSF ?-amyloid42 in cognitively healthy elders. Transl Psychiatry. 2013 Aug 20; 3:e293.
    View in: PubMed
    Score: 0.066
  103. Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, Foroud TM, Petersen RC, Aisen PS, Soares H, Toledo JB, Shaw LM, Trojanowski JQ, Weiner MW, McDonald BC, Farlow MR, Ghetti B, Saykin AJ. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One. 2013; 8(7):e70269.
    View in: PubMed
    Score: 0.066
  104. Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC, Goate AM. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 2013 Apr 24; 78(2):256-68.
    View in: PubMed
    Score: 0.065
  105. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, Umek R, Vandijck M, Salamone S, Bittner T, Shaw LM, Stephenson D, Bain L, Zetterberg H. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement. 2013 Mar; 9(2):137-40.
    View in: PubMed
    Score: 0.064
  106. Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, Rikkert MO, Verbeek MM, Spiru L, Blennow K, Trojanowski JQ, Shaw LM, Visser PJ. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med. 2013 May; 43(5):911-20.
    View in: PubMed
    Score: 0.062
  107. Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H. Analytical aspects of molecular Alzheimer's disease biomarkers. Biomark Med. 2012 Aug; 6(4):377-89.
    View in: PubMed
    Score: 0.062
  108. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2012 Jan; 8(1):65-73.
    View in: PubMed
    Score: 0.059
  109. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011 Oct; 68(10):1257-66.
    View in: PubMed
    Score: 0.057
  110. Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytical platforms for cerebrospinal fluid measures of ?-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011 Sep; 68(9):1137-44.
    View in: PubMed
    Score: 0.057
  111. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011 Jan 04; 76(1):69-79.
    View in: PubMed
    Score: 0.055
  112. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010 Aug; 67(8):949-56.
    View in: PubMed
    Score: 0.054
  113. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010 Jul 13; 75(2):143-51.
    View in: PubMed
    Score: 0.054
  114. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Weiner MW, Jagust WJ. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010 Jul 20; 75(3):230-8.
    View in: PubMed
    Score: 0.053
  115. Nettiksimmons J, Harvey D, Brewer J, Carmichael O, DeCarli C, Jack CR, Petersen R, Shaw LM, Trojanowski JQ, Weiner MW, Beckett L. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging. 2010 Aug; 31(8):1419-28.
    View in: PubMed
    Score: 0.053
  116. Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol. 2010 Jun; 67(6):688-96.
    View in: PubMed
    Score: 0.053
  117. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010 Jan 19; 74(3):201-9.
    View in: PubMed
    Score: 0.052
  118. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA. Relationships between biomarkers in aging and dementia. Neurology. 2009 Oct 13; 73(15):1193-9.
    View in: PubMed
    Score: 0.051
  119. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009 Jul 28; 73(4):287-93.
    View in: PubMed
    Score: 0.050
  120. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009 Jul 28; 73(4):294-301.
    View in: PubMed
    Score: 0.050
  121. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR, Weiner MW. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009 Apr; 132(Pt 4):1067-77.
    View in: PubMed
    Score: 0.049
  122. Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, Spindler M, Deik A, Chen-Plotkin A, Siderowf A, Dahodwala N, Weintraub D, Shaw LM, Trojanowski JQ, Vaishnavi SN, Wolk DA, Mechanic-Hamilton D, Morley JF, Duda JE, Grossman M, Cousins KAQ. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology. 2021 04 06; 96(14):e1855-e1864.
    View in: PubMed
    Score: 0.028
  123. Coughlin DG, Phillips JS, Roll E, Peterson C, Lobrovich R, Rascovsky K, Ungrady M, Wolk DA, Das S, Weintraub D, Lee EB, Trojanowski JQ, Shaw LM, Vaishnavi S, Siderowf A, Nasrallah IM, Irwin DJ, McMillan CT. Multimodal in?vivo and postmortem assessments of tau in Lewy body disorders. Neurobiol Aging. 2020 12; 96:137-147.
    View in: PubMed
    Score: 0.027
  124. Bernath MM, Bhattacharyya S, Nho K, Barupal DK, Fiehn O, Baillie R, Risacher SL, Arnold M, Jacobson T, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, Saykin AJ. Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers. Neurology. 2020 05 19; 94(20):e2088-e2098.
    View in: PubMed
    Score: 0.026
  125. Korecka M, Figurski MJ, Landau SM, Brylska M, Alexander J, Blennow K, Zetterberg H, Jagust WJ, Trojanowski JQ, Shaw LM. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. Clin Chem. 2020 04 01; 66(4):587-597.
    View in: PubMed
    Score: 0.026
  126. Garrett SL, McDaniel D, Obideen M, Trammell AR, Shaw LM, Goldstein FC, Hajjar I. Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment. JAMA Netw Open. 2019 12 02; 2(12):e1917363.
    View in: PubMed
    Score: 0.026
  127. Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K. Elecsys? Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem. 2019 Oct; 72:30-38.
    View in: PubMed
    Score: 0.025
  128. Timmers M, Bar?o S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K, Bogert J, Shaw LM, Engelborghs S, Moechars D, Mercken M, Van Nueten L, Tritsmans L, de Strooper B, Streffer JR. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. J Alzheimers Dis. 2017; 56(4):1437-1449.
    View in: PubMed
    Score: 0.021
  129. Chapuis J, Flaig A, Grenier-Boley B, Eysert F, Pottiez V, Deloison G, Vandeputte A, Ayral AM, Mendes T, Desai S, Goate AM, Kauwe JSK, Leroux F, Herledan A, Demiautte F, Bauer C, Checler F, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Albert M, Moghekar A, O'Brien R, Peskind ER, Malmanche N, Schellenberg GD, Dourlen P, Song OR, Cruchaga C, Amouyel P, Deprez B, Brodin P, Lambert JC. Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol. 2017 06; 133(6):955-966.
    View in: PubMed
    Score: 0.021
  130. Pannee J, Gobom J, Shaw LM, Korecka M, Chambers EE, Lame M, Jenkins R, Mylott W, Carrillo MC, Zegers I, Zetterberg H, Blennow K, Portelius E. Round robin test on quantification of amyloid-? 1-42 in cerebrospinal fluid by mass spectrometry. Alzheimers Dement. 2016 Jan; 12(1):55-9.
    View in: PubMed
    Score: 0.019
  131. Ramanan VK, Nho K, Shen L, Risacher SL, Kim S, McDonald BC, Farlow MR, Foroud TM, Gao S, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Aisen PS, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, De Jager PL, Yu L, Bennett DA, Saykin AJ. FASTKD2 is associated with memory and hippocampal structure in older adults. Mol Psychiatry. 2015 Oct; 20(10):1197-204.
    View in: PubMed
    Score: 0.018
  132. Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM, McCluskey L, Elman L, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology. 2010 Dec 07; 75(23):2079-86.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.